Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Cancer Lett. 2013 Jul 12;339(1):144–151. doi: 10.1016/j.canlet.2013.07.006

Figure 3. Effects of systemic administration of LIF on MTC tumor xenografts.

Figure 3

A, Athymic mice bearing TT and MZ-CRC-1 xenografts were treated with ten doses of LIF (1 mg/kg/dose) via tail vein injection every two days beginning at day 20 after tumor implantation. The control group was treated with the vehicle only. Mice were observed until 40 days after the termination of LIF treatment. Data are mean μ SEM (n=4). B, Individual monitoring of tumor relapse of LIF-treated TT xenografts in (A). C, Body weight changes of animals at the end of the treatment. Data are mean μ SEM (n=4).